AGER抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: 231 cells, Primary antibody: P06957(AGER Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P06957(AGER Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06957(AGER Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

The receptor for advanced glycation end-products (RAGE), encoded by the AGER gene, is a multiligand transmembrane protein belonging to the immunoglobulin superfamily. Initially identified for its role in binding AGEs (harmful compounds formed during hyperglycemia), RAGE has since been implicated in diverse pathological processes, including chronic inflammation, diabetes complications, neurodegenerative diseases, and cancer progression. Its activation by ligands such as HMGB1. S100 proteins, and amyloid-β triggers pro-inflammatory signaling pathways (e.g., NF-κB and MAPK), driving oxidative stress and cellular dysfunction.

AGER antibodies, developed to target RAGE or its ligands, aim to disrupt these pathogenic interactions. Research highlights their therapeutic potential in diabetic complications (retinopathy, nephropathy), Alzheimer’s disease (reducing amyloid-β toxicity), and metastatic cancers (inhibiting RAGE-mediated invasion). Soluble RAGE (sRAGE), a natural decoy receptor, has inspired antibody designs to mimic its ligand-neutralizing function. Challenges remain in optimizing specificity, minimizing off-target effects, and ensuring efficient tissue delivery. Recent preclinical studies demonstrate promising outcomes, though clinical translation is ongoing. AGER antibodies represent a strategic approach to modulating RAGE’s dual role as both a sensor of damage-associated molecules and a driver of chronic diseases.